Health
Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals – News-Medical.Net
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe…
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate the safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.
Opaganib potentially minimizes the likelihood of resistance due to viral mutations by targeting a human cell component involved…
-
Noosa News20 hours agoIncrease in extreme weather events poses ‘substantial risk’ to blood supplies, researchers warn
-
Noosa News10 hours agoAustralians tell ABC’s Your Say how they saw the second leaders debate
-
Noosa News14 hours agoManjimup engineer turns previously wasted avocados into liquid gold
-
Noosa News9 hours agoPeter Dutton insists there’s enough water for his seven nuclear plants, contradicting shadow frontbencher